Company Description
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.
Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.
Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells.
The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers.
Akari Therapeutics, Plc is headquartered in Tampa, Florida.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Abizer Gaslightwala |
Contact Details
Address: 401 East Jackson Street, Suite 3300 Tampa, Florida 33602 United States | |
| Phone | 929 274 7510 |
| Website | akaritx.com |
Stock Details
| Ticker Symbol | AKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001541157 |
| CUSIP Number | 00972G405 |
| ISIN Number | US00972G4055 |
| Employer ID | 98-1034922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Abizer Gaslightwala | Chief Executive Officer, President and Director |
| Kameel D. Farag | Interim Chief Financial Officer |
| Dr. Satyajit Mitra Ph.D. | Executive Director and Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 3, 2026 | D | Notice of Exempt Offering of Securities |
| May 22, 2026 | PRE 14A | Other preliminary proxy statements |
| May 22, 2026 | 8-K | Current Report |
| May 21, 2026 | RW | Filing |
| May 19, 2026 | 10-Q | Quarterly Report |
| May 18, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 8, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 15, 2026 | EFFECT | Notice of Effectiveness |
| Apr 10, 2026 | POS AM | Post-Effective amendments for registration statement |